CNBCLean R·
AstraZeneca stock dives 9% after heart drug trial misses target
A late-stage clinical trial failed to miss its primary endpoint, U.K.'s laregst drugmaker said Thursday.
Read at CNBC →
New York TimesLean L
A late-stage clinical trial failed to miss its primary endpoint, U.K.'s laregst drugmaker said Thursday.
<iframe src="https://statesidedaily.com/embed/cluster/e101b53ebf56662d43db966ee4681d9bbbffaa46" width="100%" height="320" style="border:0;max-width:680px" loading="lazy" title="AstraZeneca stock dives 9% after heart drug trial misses target"></iframe>